NEURL2

Across TCGA pan-cancer cohorts, NEURL2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of NEURL2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NEURL2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NEURL2 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

LIHC, COAD, and LUAD are the cancer types where NEURL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEURL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.753	<.001	9	view →
COAD	All	All	+0.461	<.001	8	view →
LUAD	All	II,III,IV	+0.321	<.001	8	view →
UCEC	All	All	−0.878	<.001	6	view →
BRCA	Female	All	−0.461	<.001	6	view →
KICH	Female	All	+0.647	.001	5	view →
LUSC	All	All	+0.230	.003	4	view →
CHOL	All	All	+0.701	.001	3	view →
STAD	All	II,III,IV	+0.437	.005	3	view →
BLCA	All	IV	−0.615	.005	2	view →
READ	All	All	+0.517	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

NEURL2–LIHC

Open the LIHC breakdown →